Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Oral Nicotinamide for Actinic Keratosis Prevention in Kidney Transplant Recipients: A Pilot Double-Blind, Randomized, Placebo-Controlled Trial.

Author information

Affiliations

  • 1. The Warren Alpert Medical School of Brown University, Providence, RI.
      Authors
    • Zhang H 1
    (1 author)
  • 2. Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY.
      Authors
    • George-Washburn EA 2
    (1 author)
  • 3. Department of Dermatology, Medical University of South Carolina, Charleston, SC.
      Authors
    • Hashemi KB 3
    (1 author)
  • 4. Department of Epidemiology, School of Public Health, Brown University, Providence, RI; Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
      Authors
    • Cho E 4
    (1 author)
  • 5. Department of Dermatology, The Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, RI; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
      Authors
    • Walker J 5
    (1 author)
    • Show all (8)

ORCIDs linked to this article

Transplantation Proceedings, 12 Oct 2023, 55(9):2079-2084
https://doi.org/10.1016/j.transproceed.2023.06.016 PMID: 37838527 

Abstract 

Background

Oral nicotinamide (NAM) has shown promise in preventing actinic keratoses (AKs) in trials based outside of the United States. We assessed the efficacy of oral NAM supplementation in kidney transplant recipients with a history of keratinocyte carcinoma.

Material and methods

Patients enrolled in a 2-week run-in phase, during which NAM 1000 mg was taken twice daily. After a washout period, patients who tolerated the run-in phase were randomized to NAM 500 mg twice daily or placebo. At baseline, 4, 8, and 12 months, dermatologists conducted full-body skin exams to document area-specific AKs. Routine lab work was collected to ensure the stability of renal allograft function.

Results

The dosage was reduced from 1000 to 500 mg due to gastrointestinal symptoms in the run-in phase. Patients were randomized to NAM (n = 10) or placebo (n = 11). At 12 months, mean AK count was 30.8 (95% CI -11.7-73.4) for NAM and 26.6 (95% CI 10.8-42.5) for placebo. The difference in percent AK count change at 12 months compared with baseline was 259.8% (95% CI -385.9 to 905.5) for NAM and 72.4% (95% CI -118.6 to 263.5) for placebo. The between-group difference in percent AK change was not significant (P = .38). There was no attrition in the placebo group and 40% attrition in the NAM arm.

Discussion

Nicotinamide did not decrease AK development among kidney transplant recipients. Limitations include drug tolerability, small sample size, and single-center trial nature.

Full text links 

Read article at publisher's site: https://doi.org/10.1016/j.transproceed.2023.06.016

Citations & impact 

Impact metrics

2
Citations
Jump to Citations

Article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.

Funding 

Funders who supported this work.

Prevent Cancer Foundation